Julia Schaletzky

Executive Director, Center for Emerging and Neglected Diseases (CEND) and Immunotherapy and Vaccine Research Institute (IVRI)

Originally from Germany, Julia trained as a biochemist at Bayreuth University and completed her undergraduate degree at the Max-Planck-Institute of Biochemistry in Martinsried. She then went abroad to obtain her PhD at Harvard Medical School, focusing on translocation of proteins across the endoplasmic reticulum membrane. After completing her PhD, Julia joined Cytokinetics, a biotechnology company in South San Francisco. During her 11 years at Cytokinetics, Julia and her team focused on discovering and developing novel, first-in-class medicines against heart failure and neurodegenerative disorders such as ALS, which are currently in Phase III clinical trials. In addition, she took on several pro-bono projects stemming from academic collaborations, working after hours on successful screens against trypanosomiasis (sleeping sickness), malaria and toxoplasmosis. Julia is passionate about treating neglected and emerging diseases, establishing effective collaboration between academia and industry and about translating basic science into new companies and ultimately cures.